This presentation describes a study of the use of the new fixed-dose antimalarial combination ASMQ (artesunate + mefloquine) in Acre state in the Amazon region of Brazil. There was a significant reduction in the number of malaria cases, the ratio of Plasmodium falciparum cases to P. vivax cases, and the recurrence rate; there were no reports of serious adverse effects and only one non-serious adverse event. It is concluded, subject to the limitations of the study, that the trial was successful.
Presentation from ‘The ASMQ Fixed-Dose Combination to treat Malaria: From Blueprint to Use in the Field’. Symposium from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 19 November 2009.